Mizuho analyst Salim Syed lowered the firm’s price target on Cytokinetics (CYTK) to $84 from $103 and keeps an Outperform rating on the shares. The firm updated the company’s model post the Q1 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Promising SEQUOIA-HCM Study Data Justifies Buy Rating for Cytokinetics
- Cytokinetics presents additional data related to Aficamten
- Cytokinetics Announces Key Decisions at Annual Meeting
- Cytokinetics to host symposium on Contemporary Landscapes in Muscle Biology
- Buy Rating for Cytokinetics Driven by Promising Phase 3 Results of Aficamten in Hypertrophic Cardiomyopathy